International sales propel Imatron to fourth straight profitable quarter

Article

Firm takes over some distribution from Siemens The good times continue to roll at ultrafast CT developer Imatron.The South San Francisco, CA, company last month announced itsfourth consecutive profitable quarter, with record revenues andan

Firm takes over some distribution from Siemens

The good times continue to roll at ultrafast CT developer Imatron.The South San Francisco, CA, company last month announced itsfourth consecutive profitable quarter, with record revenues andan $800,000 improvement in earnings over the same period lastyear.

Imatron has enjoyed growing demand this year for its ultrafastCT technology after sluggish years in 1992 and 1993. Several recentlyreleased studies have supported the clinical utility of its technologyin detecting early stages of coronary artery disease in asymptomaticpatients (SCAN 9/14/94).

The Pacific Rim in particular has been a hot spot for Imatron.The company last month landed a $4.5 million contract from Thailandand a $2.5 million order from Taiwan for C-150 scanners.

Imatron's revenues for the third quarter (end-September) were$8.9 million, a company record that reflected the shipment offive C-150 systems. The figure is 4% higher than the $8.6 millionposted in the third quarter of 1993. The numbers do not includerevenue from the Thailand and Taiwan sales, which will registerin the company's fourth quarter.

Imatron's earnings present an even rosier picture. The companyhad net income for the quarter of $582,000, compared to a lossof $223,000 in the same period last year. The firm's operatingprofit was $711,000.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.